Association Of Hematological Toxicity (Tox) And Outcome To Doxorubicin (Dox) In Advanced Soft Tissue Sarcoma (Sts): A Retrospective Analysis Of The Eortc-Soft Tissue And Bone Sarcoma Group Database.

10544 Background: DOX pharmacokinetics vary substantially between patients leading to large differences in systemic drug levels. Given potential dose-effect relations, patients with the greatest tox may also have the best outcome. We assessed whether severity of hematological tox during treatment is associated with outcome in advanced STS patients treated with first-line DOX (monotherapy; 75 mg/m2 q 3 weeks). Methods: Worst tox (anaemia, leukopenia, neutropenia and thrombocytopenia) scored during treatment according to CTCAE v4.0 was included in this analysis. Differences in overall survival (OS), progression free survival (PFS) and response rate (RR) between patients with or without high haematological tox (grade 0-2 vs 3-4) were assessed using conventional statistical tests in landmarked subsets, to avoid bias from patients stopping treatment early. Potential confounders were collected including relative dose intensity (RDI), patients’ and tumor characteristics. Results: In 557 patients eligible for thi...